449P - Utility of screening tool for assessment of chemotherapy induced peripheral neuropathy in cancer patients

Background

To evaluate the utility of screening tool in assessment of chemotherapy induced peripheral neuropathy (CIPN) among patients receiving chemotherapy for any cancers by using CIPN screening tool.

Methods

A prospective observational study was conducted in the medical oncology wards of tertiary care hospital in Southern India. The data was extracted from the patient’s evaluation and medical records with known histological malignancies and at least one chemotherapeutic drug prescribed in it. Patients and their caretakers were interviewed after 3rd cycle of chemotherapy and followed up till the end of chemotherapy. Pre-designed and validated questionnaire was administered to the subjects, eviQ screening tool was applied for evaluating (CIPN) symptoms and severity grading was assessed by using CTCAE version 4.3.

Results

A total of 101 cancer patients were recruited into the study based on inclusion and exclusion criteria. 45.5% of patients have developed CIPN. 69.5% of subjects had grade-2 and 30.43% of subjects had developed grade 3 peripheral neuropathy. Gender distribution of subjects had shown that females were more prone to develop CIPN (82.6%). Subjects at the age group of 50-59 years old stood first (23.91%) for CIPN followed by 40-49 years old (21.78%). In Individual therapy paclitaxel (77.7%) showed the higher rate of CIPN followed by cisplatin (26.6%), where as in combination therapy paclitaxel with carboplatin had shown the higher rate of CIPN (53.84%).

Conclusions

Current screening tool is effective for early detection and will give better incidence rate of chemotherapy induced peripheral neuropathy then routine clinical evaluation.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.